Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB IL-10/IL-15 CD19-CAR NK in B-cell NHL
NCT06707259Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-cd19 interleukin-10 + interleukin-15 chimeric antigen receptor natural killer cells in B-cell non-Hodgkin lymphoma, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Incidence of dose limiting toxicity at 28 days. Started Dec 2024; status: recruiting.
02
Drugs
anti-cd19 interleukin-10 + interleukin-15 chimeric antigen receptor natural killer cells
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06707259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06707259.